Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Oxford BioMedica plc, a leading gene therapy company, today announces that the first dose level of RetinoStat is safe and well-tolerated at one month following treatment.

22 Jun 2011

Smoking may increase risk of death from prostate cancer

Men who are diagnosed with prostate cancer and who are also smokers have an associated increased risk of all-cause, cardiovascular and prostate cancer-specific death, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

USPTO upholds ten amended claims of SANUWAVE's '119 patent

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today reported that the U.S. Patent and Trademark Office (USPTO) issued a reexamination certificate upholding ten amended claims of SANUWAVE's U.S. Patent No. 6,080,119 following a third party's ex parte reexamination request.

15 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

ESC publishes position paper to raise the profile of vulnerable plaques

The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation.

15 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

RegeneRx Biopharmaceuticals, Inc. has announced that thymosin beta 4 (Tβ4) can activate a unique subpopulation of resident adult epicardial stem cells such that they recapture embryonic potential, proliferate, migrate and differentiate into functional heart muscle (cardiomyocytes), according to a research paper published online today in Nature.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Silencing two microRNAs may help treat age-related macular degeneration

Blocking two tiny molecules of RNA - a chemical cousin of DNA - appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, UT Southwestern Medical Center researchers have found.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Scientists at Queen's University Belfast have discovered proteins in frog skins which could be used to treat cancer, diabetes, stroke and transplant patients by regulating the growth of blood vessels.

7 Jun 2011

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Angiogenesis News and Research

Further Reading

Redefinition of cardiac hypertrophy term needed

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Smoking may increase risk of death from prostate cancer

NASDAQ halts Regeneron's common stock

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

USPTO upholds ten amended claims of SANUWAVE's '119 patent

Galectin strengthens cancer drug patent portfolio in Europe

ESC publishes position paper to raise the profile of vulnerable plaques

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Silencing two microRNAs may help treat age-related macular degeneration

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo